Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-17T16:32:46.159Z Has data issue: false hasContentIssue false
  • English
  • Français

Ciprofloxacin Resistance Among Nosocomial Pseudomonas aeruginosa and staphylococcus aureus in the United States

Published online by Cambridge University Press:  02 January 2015

Victor G. Coronado ,
Jonathan R. Edwards ,
David H. Culver ,
Robert P. Gaynes  and
The National Nosocomial Infections Surveillance (NNIS) System
Victor G. Coronado
Affiliation:
Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Jonathan R. Edwards
Affiliation:
Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
David H. Culver
Affiliation:
Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Robert P. Gaynes*
Affiliation:
Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
*
Hospital Infections Program, Mailstop E-68, Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, GA 30333
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

We attempted to determine if an increase in resistance to ciprofloxacin occurred among nosocomial pathogens, especially Pseudomonas aeruginosa and Staphylococcus aureus.

Methods:

We examined 1989-1992 ciprofloxacin susceptibility results from 8,517 P aeruginosa and 9,021 S aureus isolates associated with nosocomial infections reported to the National Nosocomial Infections Surveillance System.

Results:

For S aureus, 27.1% of isolates were resistant to ciprofloxacin; of methicillin-resistant S aureus isolates, 80% also were resistant to ciprofloxacin. A logistic regression model found that ciprofloxacin resistance was more common among S aureus isolated from the urinary and respiratory tracts than from other sites of isolation, and among isolates that were methicillin resistant. After controlling for these factors, the model showed a 123% increase in the odds of ciprofloxacin resistance from 1989-1990 to 1991-1992. For P aeruginosa, 4.7% of the isolates were resistant to ciprofloxacin. Resistance varied by site of infection and rose most dramatically for respiratory tract isolates from 2.0% in 1989-1990 to 5.3% in 1991-1992.

Conclusion:

Resistance to ciprofloxacin is more frequent among nosocomial S aureus than among P aeruginosa and is increasing rapidly among S aureus isolates and from selected sites among P aeruginosa isolates.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 16 , Issue 2 , February 1995 , pp. 71 - 75
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1995 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Wise, R, Andrew, JM, Edwards, LJ. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Ckemother 1983;23:559–562.CrossRefGoogle ScholarPubMed
2. Bauernfeind, A, Petermuller, C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol 1983;2:111–116.CrossRefGoogle ScholarPubMed
3. Muytjens, HL, van der Ros-van de Repe, J, van Veldhuizen, G. Comparative activities of ciprofloxacin (Bay 09867), norfloxacin, pipemidic acid, and nalidixic acid. Antimicrob Agents Ckemother 1983;24:302–306.CrossRefGoogle ScholarPubMed
4. Fass, RJ. In vitro activity of ciprofloxacin (Bay 09867). Antimicrob Agents Chemother 1983;24:568–571.CrossRefGoogle Scholar
5. Neu, HC. Bacterial resistance to fluoroquinolones. Rev Infect Dis 1988;10:S57–S63.CrossRefGoogle ScholarPubMed
6. Satta, G, Siddu, D, Cornaglia, G, Pruna, M. Ciprofloxacin and resistance to antibiotics in gram-positive and gram-negative bacteria. Rev Infect Dis 1988;10:S65–S66.Google Scholar
7. Frei, R, Bindschedler, M, Stader, H, Reber, H, Follath, E Emergence of resistance to ciprofloxacin during therapy. Rev Infect Dis 1988;10:S68–S71.Google Scholar
8. Chin, NX, Clynes, N, Neu, HC. Resistance to ciprofloxacin appearing during therapy. Am J Med 1989;87:28S–31S.CrossRefGoogle ScholarPubMed
9. Baillie, L. Ciprofloxacin resistant Pseudomonas aeruginosa strain. Med Lab Sci 1989;46:92–93. Letter.Google ScholarPubMed
10. Wiedemann, B, Zuhlsdorf, MT Brief report: resistance develop ment to fluoroquinolones in Europe. Am J Med 1989;87:9S–11S.CrossRefGoogle Scholar
11. Raviglione, MC, Boyle, JF Mariuz, P Pablos-Mendez, A, Cortes, H, Merlo, A. Ciprofloxacin-resistant methicillin-resistant Staphylo-COCCUS aureus in an acute-care hospital. Antimicrob Agents Chemother 1990;34:2050–2054.CrossRefGoogle Scholar
12. Daum, TE, Schaberg, DR, Terpenning, MS, Sottile, WS, Kauffman, CA. Increasing resistance of Staphylococcus aureus to cip rofloxacin. Antimicrob Agents Chemother 1990;34:1862–1863.CrossRefGoogle Scholar
13. Chamberland, S, Malouin, F Rabin, HR, Schollaardt, T, Parr, TR Jr, Bryan, LE. Persistence of Pseudomonas aeruginosa during cip rofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency. J Antimicrob Chemother 1990;25:995–1010.CrossRefGoogle Scholar
14. Peterson, LR, Quick, JN, Jensen, B, et al. Emergence of cip rofloxacin resistance in nosocomial methicillin-resistant Staphy-lococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S.aureus colonization. Arch Intern Med 1990:150:2151–2155.10.1001/archinte.1990.00390210111024CrossRefGoogle Scholar
15. Ball, P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significanee and therapeutic approaches. J Antimicrob Chemother 1990;26(suppl F):165–179.CrossRefGoogle ScholarPubMed
16. Blumberg, HM, Rimland, D, Carroll, DJ, Terry, P, Wachsmuth, IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus . J Infect Dis 1991;163:1279–1285.CrossRefGoogle ScholarPubMed
17. Blumberg, HM, Rimland, D, Kiehlbauch, JA, Terry, PM, Wachsmuth, IK. Epidemiologic typing of Staphylococcus aureus by DNA restriction fragment length polymorphisms of rRNA genes: elucidation of the clonal nature of a group of bacteriophage nontypeable, ciprofloxacin-resistant, methicillin-susceptible S. aureus isolates. J Clin Microbiol 1992;30:362–369.CrossRefGoogle ScholarPubMed
18. Maple, P, Hamilton-Miller, J, Brumfitt, W. Ciprofloxacin resistance in methicillin- and gentamicin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1989;8:622–624.CrossRefGoogle ScholarPubMed
19. Schaefler, S. Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones. J Clin Microbiol 1989;27:335–336.10.1128/jcm.27.2.335-336.1989CrossRefGoogle ScholarPubMed
20. Piercy, EA, Barbaro, D, Luby, JP, Mackowiak, PA. Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 1989;33:128–130.CrossRefGoogle ScholarPubMed
21. Budnick, LD. Schaefler, S. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in New York health care facilities, 1988. The New York MRSA Study Group. Am J Pub Health 1990;80:810–813.CrossRefGoogle ScholarPubMed
22. Smith, SM, Eng, RH, Bais, P, Fan-Havard, P, Tecson-Tumang, F. Epidemiology of ciprofloxacin resistance among patients with methicillin-resistant Staphylococcus aureus . J Antimicrob Chemother 1990;26:567–572.CrossRefGoogle ScholarPubMed
23. Kaatz, GW, Seo, SM, Ruble, CA Mechanisms of fluoroquinolone resistance in Staphylococcus aureus . J Infect Dis 1991;163:1080–1086.CrossRefGoogle ScholarPubMed
24. Dornbusch, K. Resistance to beta-la&m antibiotics and cip-rofloxacin in gram-negative bacilli and staphylococci isolated from blood: a European collaborative study. European Study on Antibiotic Resistance. J Antimicrob Chemother 1990;26:269–278.10.1093/jac/26.2.269CrossRefGoogle Scholar
25. George, RC, Ball, LC, Norbury, PB. Susceptibility to ciprofloxacin of nosocomial gram-negative bacteria and staphylococci isolated in the UK. J Antimicrob Chemother 1990;26(suppl F):145–156.10.1093/jac/26.suppl_F.145CrossRefGoogle ScholarPubMed
26. Barrett, MS, Jones, RN, Erwin, ME, Johnson, DM, Briggs, BM. Antimicrobial activity evaluations of two new quinolones, PD 127391 (CI-960 and AM-1091) and PD131628. Diag Microbiol Infect Dis 1991;14:389–401.CrossRefGoogle ScholarPubMed
27. Parry, ME Panzer, KB, Yukna, ME. Quinolone resistance. Susceptibility data from a 300-bed community hospital. Am J Med 1989;87:125–168.Google ScholarPubMed
28. Gaynes, RP: Culver, DH, Emori, TG, et al. The National Nosocomial Infections Surveillance (NMS) System: plans for the 1990s and beyond. Am J Med 1991;91(3B) :116S–120S.CrossRefGoogle Scholar
29. Emori, TG, Culver, DH, Horan, TC, et al. National Nosocomial Infections Surveillance (NNIS) System: description of surveillance methodology. Am Infect Control 1991:19:19–35.CrossRefGoogle Scholar
30. Gamer, JS, Jarvis, WR, Emori, TG, Horan, TC, Hughes, JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140.Google Scholar
31. SAS Institute Inc. SAS/STAT User's Guide, Version 6. 4th ed, vol. 2. Cary, NC: SAS Institute Inc; 1989.Google Scholar
32. BMDP Statistical Software Manual. Berkeley, CA University of California Press; 1983.Google Scholar
33. Sader, HS, Pignatari, AC, Hollis, RJ. Leme, I, Jones, RN. Oxacillin-and quinolone-resistant Staphylococcus aureus in Sao Paulo. Infect Control Hosp Epidemiol 1993:14:260-264.CrossRefGoogle Scholar
34. Weinstein, RA, Nathan, C, Gruensfelder, R, Kabins, SA Endemic aminoglycoside resistance in gram-negative bacilli. J Infect Dis 1980;141:338–342.CrossRefGoogle ScholarPubMed
35. Diver, JM, Schollaardt, T, Rabin, HR, Thorson, C, Bryan, LE. Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrob Agents Chemother 1991:35:1538–1546.CrossRefGoogle ScholarPubMed
36. Ferguson, MI, Scott, EM, Collier, PS. Development of resistance to ciprofloxacin in nutrient-rich and nutrient-limited growth conditions in vitro by Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1991;35:2649–2651.CrossRefGoogle ScholarPubMed
37. Gaynes, RP, Culver, DH. Resistance to imipenem among selected gram-negative bacilli in the United States. Infect Control Hosp Epidemiol 1992;13:10-14.CrossRefGoogle Scholar
38. Panlilio, AL, Culver, DH, Gaynes, R, Toison, JS, Marione, WJ. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 19751991. Infect Control Hosp Epidemiol 1992;13:582-586.CrossRefGoogle Scholar